Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDUFA IV Fix For FDA Performance On Standard Reviews Advocated By BIO

Executive Summary

Prescription Drug User Fee Act negotiations should address the discrepancy in FDA performance on approval times for standard and priority review applications, Biotechnology Industry Organization's Amit Sachdev said

You may also be interested in...



PDUFA IV Negotiations Underway With FDA, Industry Working In Harmony

PhRMA will pursue earlier postmarketing commitment negotiations with FDA as part of a limited industry agenda for the third reauthorization of the Prescription Drug User Fee Act

PDUFA IV Negotiations Underway With FDA, Industry Working In Harmony

PhRMA will pursue earlier postmarketing commitment negotiations with FDA as part of a limited industry agenda for the third reauthorization of the Prescription Drug User Fee Act

Key To First-Cycle Approval Is To Meet Early And Often, Consultants Tell FDA

An independent analysis of FDA's first-cycle review performance provides support for the agency's request for additional funding for pre-submission meetings

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS046919

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel